Abstract
The Institute for Clinical and Economic Review’s (ICER) Unsupported Price Increase (UPI) reports aim to identify drugs with substantial price increases without adequate evidence to justify the increases. ICER’s methodology and criteria for accepting evidence have received critique, and there is limited research on how different types of manufacturer-submitted evidence are appraised. Our objectives were to review ICER’s determinations for manufacturer-submitted evidence and identify acceptance and rejection trends.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
